Clinical Trial Update: PhaseⅠ/Ⅱ Study of URLC10-177 and TTK-567 Peptide Vaccine Combined With CpG7909 in Patients With Esophageal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase I/II clinical trial is evaluating URLC10-177 and TTK-567 peptide vaccine with CpG7909 in esophageal cancer, sponsored by Wakayama Medical University; cu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• CpG7909 (CpG7909)
• TTK-567 peptide vaccine (TTK-567 peptide vaccine)
• URLC10-177 (URLC10-177 peptide)

Snippet

Sponsor: Wakayama Medical University | Conditions: Esophageal Cancer | Phase 1, Phase 2 | Status: UNKNOWN